Enter the last name, specialty or keyword for your search below.
Research Interests: Human pluripotent stem cells; cell fate determination/plasticity; disease modeling
For more than 12 years, Dr. Kim has been studying the status of pluripotency and reprogramming using human pluripotent stem cells (hPSCs). As a postdoctoral fellow (2005-2011), her research focus was to study the status of pluripotency and the propensity of neural differentiation in more than 30 different hPSCs. This study allowed her to understand that all different hPSCs stand at a different stage of pluripotency, marked by the expression level of mir-371 cluster, which is significantly correlated with different levels of propensity toward neural differentiation, and even to a final neuronal differentiation such as dopaminergic neurons (Kim et al., Cell Stem Cell, 2011).
With extensive experience in postdoctoral training period, she became a Director of Stem Cell Core Facility at Johns Hopkins School of Medicine (2011-2016), where she has supported stem cell research community inside and outside of Johns Hopkins, by sharing her expertise and techniques such as patient-specific hiPSC generation, direct differentiation, genetic modification of hPSC, and one-to-one training.
Now she began a new career as an independent PI with her own laboratory since February 2017.
The Kim lab is focusing on enhancing the capacity of human pluripotent stem cells (hPSCs)-based approaches. For more efficient usage of hPSCs, Kim lab is trying to make several points of improvement, such as a novel approach of hiPSCs generation, novel technology or renovated procedure of current genetic modification steps, and broader application of hPSCs as a cellular platform to cope with human autoimmune diseases. In addition, Kim lab studies controlling cellular fates with temporal and spatial precision in hPSCs using opto-signaling pathway system.
Kim H, Lee G, Ganat Y, Papapetrou EP, Lipchina I, Socci ND, Sadelain M, Studer L. miR-371-3 Expression predicts neural differentiation propensity in human pluripotent stem cells. Cell Stem Cell 2011 8:695-706. PMID 21624813
Kim H, Studer L. iPSCs put to the test. Nature Biotechnology 2011 29:233-5. PMID: 21390027
Choi IY, Lim H, Estrellas K, Mula J, Cohen TV, Zhang Y, Donnelly CJ, Richard JP, Kim YJ, Kim H, Kazuki Y, Oshimura M, Li HL, Hotta A, Rothstein J, Maragakis N, Wagner KR, Lee G. Concordant but Varied Phenotypes among Duchenne Muscular Dystrophy Patient-Specific Myoblasts Derived using a Human iPSC-Based Model. Cell Report 2016 15(10):2301-12. PMID: 27239027
Lee G, Ramirez CN, Kim H, Zeltner N, Liu B, Radu C, Bhinder B, Kim YJ, Choi IY, Mukherjee-Clavin B, Djaballah H, Studer L. Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nature Biotechnology 2012 30:1244-8. PMID: 23159879
Xi Q, Wang Z, Zaromytidou A, Zhang X, Chow-Tsang L, Liu J, Kim H, Manova-Todorova K, Kaartinen V, Studer L, Mark W, Patel D and Massagué J. A poised chromatin platform for TGF-? access to master regulators. Cell 2011 147:1511-24. PMID: 22196728
Language Assistance Available:
© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.
